Jefferies upgraded Sumitomo Pharma to Buy from Hold with a price target of 1,050 yen, up from 830 yen ahead of a new medium-term plan scheduled to be released on April 28. The firm expects Sumitomo to turn profitable next year and "sustain growth for the foreseeable future," the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on DNPUF: